Navigation Links
EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics

MUNICH, Feb. 1, 2012 /PRNewswire/ -- Exosome Diagnostics GmbH, a subsidiary of Exosome Diagnostics, Inc., and the Department of Dermatology at the Ludwig Maximilian University (LMU) announces the awarding of a EUR one million grant from the German Federal Ministry for Education and Research (BMBF) to develop blood-based diagnostic tests from the stable RNA content accessible in plasma-derived exosomes.  The grant will help fund development of exosome-based diagnostics technology to detect tumor specific mutations in the blood from patients with malignant cancer in order to enable monitoring of disease recurrence, aid therapy selection and possibly improve early tumor detection. The grant was awarded under the Leading-Edge Cluster program "m4 – Personalized Medicine and Targeted Therapies."

Cancer tumor-specific somatic mutations such as those found in the RAF and RAS gene families will be investigated by coupling exosome-based technology with next-generation sequencing and qPCR instrument platforms.  Exosome Diagnostics GmbH intends to offer clinical diagnostic tests developed under this project as a commercial laboratory service performed out of the Company's St. Paul, Minnesota, United States and Munich, Germany, cGLP laboratories.

"Exosome technology allows us to repeatedly interrogate tumor, inflammatory and immune response gene signatures in a minimally invasive manner," said James McCullough, chief executive officer, Exosome Diagnostics. "We are essentially looking for genetic needles in a haystack of biological material.  By isolating exosomes we avoid a host of complicating factors, such as circulating enzymes, platelets, and other interfering factors, that are a significant detriment to achieving diagnostic sensitivity and reproducibility."

Microvesicles, of which exosomes are a subset, contain large quantities of tumor-derived messenger RNA (mRNA) found in biofluids outside of tumor cells.  Microvesicle mRNA, is of high quality and includes both small and large RNA molecules in multiple copies.  The microvesicle/exosome population provides a stable source of RNA in blood, urine and CSF that, when isolated and prepared properly, can produce high diagnostic sensitivity for key gene mutations and gene expression levels.  

Exosome RNA biofluid diagnostic tests have potentially significant implications for disease identification, treatment and monitoring.  In many cases, tumor tissue is difficult to attain and requires either a biopsy or a surgical procedure. Repeated blood and urine measurements are minimally invasive and can provide critical information on a tumor's genetic status over time, through the course of treatment and recurrence.

"I am very excited about this project," says Dr. Carola Berking, Professor of Dermatology at Ludwig Maximilian University.  "The prospects of detecting specific cancer mutations by a fast and simple blood or urine sampling would be a major advancement and facilitate the whole procedure of personalized medicine starting from the decision to treat, which therapies to use, to the immediate monitoring of treatment effect."

To increase the capability of exosome-based technology, Exosome Diagnostics has been developing an ultra-deep, multiplexed sequencing method for use with mRNA from blood and urine exosome preparations.  The ultra-deep sequencing method allows for high sensitivity detection of rare gene mutations upregulated into exosomes by cancer cells against a background of normal or "wild-type" genes.  The massively parallel nature of next generation sequencing technology allows for hundreds of mutations to be interrogated simultaneously. Many of the mRNA targets to which exosome nucleic acid isolation and extraction technology is currently being applied are of importance in targeted molecular therapy clinical development programs.

About the Leading-Edge Cluster program "m4 – Personalized Medicine and Targeted Therapies"

The project is funded by the program "m4 – Personalized Medicine and Targeted Therapies" for which the Munich Biotech Cluster was awarded "Leading-Edge cluster status" by the German Federal Ministry of Research and Education (BMBF) in 2010. For a 5 year period, the program is funded with EUR 40 million from the BMBF, which are complemented by EUR 40 million from the participating companies in more than 40 cooperative R&D projects from industry and scientific institutions. The Bavarian Ministry of Economic Affairs, Infrastructure, Transport and Technology supports the cluster management agency BioM and particular components of the concept with an additional EUR 12 million. For more information please visit

About Ludwig Maximilian University (LMU)

The Department of Dermatology and Allergology at the Ludwig Maximilian University of Munich (Dermatology at LMU) is one of the largest dermatology clinics in Europe and worldwide with more than 50 doctors, 155 beds, more than 90,000 outpatient visits and 5,500 inpatient visits per year. Each year more than 5,000 visits by melanoma patients are scheduled at the dermato-oncology department headed by Prof. Dr. med. Carola Berking. The treatments include surgical excisions, adjuvant therapy, systemic chemotherapy, radiation and immunotherapy. Further, many clinical trials are carried out at Dermatology at LMU offering patients experimental therapies such as BRAF/MEK/c-Kit inhibitors or ipilimumab. Prof. Berking acts as Principal Investigator on several such trials and is considered a Key Opinion Leader in the field. For more information please visit

About Exosome Diagnostics

Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are shed into all biofluids, including blood, urine, and CSF, providing a stable source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural stability to achieve high sensitivity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.  The Company is commercializing in-vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of disease. The Company maintains facilities in New York, NY, St. Paul, MN and Munich/Martinsried, Germany. For more information, please visit

SOURCE Exosome Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Global Clinical Trial Management Systems Market Worth $1300.4 Million by 2016
2. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
3. iBio, Inc. Prices $10 Million Public Offering
4. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
5. Roka Bioscience Secures $47.5 Million in Series D Financing
6. VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer
7. Vermillion Sharpens Focus and Streamlines Operations in 2012
8. Bionovo Announces $5 Million Financing
9. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
10. Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments
11. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
(Date:10/27/2015)... -- In the present market scenario, security is one ... verticals such as banking, healthcare, defense, electronic gadgets, and ... secure & simplified access control and growing rate of ... bank accounts, misuse of users, , and so on. ... and smartphones are expected to provide potential opportunities for ...
(Date:10/26/2015)... October 26, 2015 ... adds Biometrics Market Shares, ... as well as Emerging Biometrics Technologies: ... to its collection of IT and ... . --> ...
Breaking Biology News(10 mins):